Editas Medicine, Inc. Common Stock EDIT
$3.46
+0.87%
at last close
Market Cap$530.98 million
P/E Ratio—
Div Yield—
Volume3.91M
52-Week Range
$1.29$4.54
Key Stats
- Today's Range
- $3.24 – $3.50
- 50-Day Range
- $2.13 – $3.94
- 52-Week Range
- $1.29 – $4.54
- Volume
- 3.91 million shs
- Average Volume
- 2.26 million shs
- Market Cap
- $530.98 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 120.46
- Price / Sales
- 13.72
Short Interest
- Short Interest
- 6.37%
- Days to Cover
- 5.54
Financials (TTM)
- Revenue
- $38.69 million
- Net Income
- $-108,954,000
- Net Margin
- -281.59%
- Return on Equity
- -2471.73%
- Debt-to-Equity
- —
About Editas Medicine, Inc. Common Stock
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.